Novo Nordisk (NVO) Slashes Wegovy Price in India Up to 37% as Board Vote Nears; U.S. Access Deal Sets 2026 Shift — Nov. 11, 2025

Novo Nordisk (NVO) Slashes Wegovy Price in India Up to 37% as Board Vote Nears; U.S. Access Deal Sets 2026 Shift — Nov. 11, 2025

Novo Nordisk cuts Wegovy prices in India up to 37% and faces a pivotal board vote this week, as a U.S. pricing/access deal looms for 2026. Date: November 11, 2025 Key takeaways India: Wegovy gets markedly cheaper — and it’s about more than price Novo Nordisk cut Wegovy’s Indian list prices across the dose range, with the monthly 2.4 mg pack now at ₹16,400 (down from ₹24,389 at launch) and the 0.25 mg starter at ₹10,850 (from ₹16,260). The company confirmed the reductions amid a fast‑evolving obesity market in the country. Reuters updated its initial “up to 33%” reporting to
11 November 2025
Sky on Fire Tonight: Giant ‘Solar Canyon’ Aims 800‑km/s Wind at Earth—Northern Lights Could Ignite 15 U.S. States & Test Global Tech

NOAA Issues G4 ‘Severe’ Geomagnetic Storm Watch for Nov. 12 After X5.1 Solar Flare — Northern Lights Possible as Far South as Indiana Tonight (Nov. 11)

Published: November 11, 2025 Key takeaways What changed today (Nov. 11) NOAA’s Space Weather Prediction Center (SWPC) posted a G4 (Severe) watch for Nov. 12, citing multiple coronal mass ejections (CMEs) now en route — including the most energetic, linked to today’s X5.1 flare that peaked at 10:04 UTC (5:04 a.m. EST). The agency says the latest CME appears partial‑halo and fast, and while forecast timing remains uncertain, confidence is high that Earth will catch at least a glancing blow. Space Weather Prediction Center NOAA’s 3‑Day Forecast (issued 18:40 UTC) backs up the upgrade with a Kp breakdown that reaches
11 November 2025
3I/ATLAS Today (Nov. 11, 2025): Interstellar Comet Reappears with Growing Ion Tail, Morning-Sky Return & Rumor Control

3I/ATLAS Today (Nov. 11, 2025): Interstellar Comet Reappears with Growing Ion Tail, Morning-Sky Return & Rumor Control

Updated: November 11, 2025 Key points at a glance What’s new today A longer, sharper tail. Astrophysicist Gianluca Masi reports that 3I/ATLAS’s ion tail has lengthened to at least 0.7°, with an anti‑tail also apparent in stacked exposures taken this morning (Nov. 11) from Italy. The session was conducted at low altitude above the eastern horizon under a bright Moon, underscoring just how active and structured the comet has become post‑perihelion. The Virtual Telescope Project 2.0 Visible again before dawn. As predicted, 3I/ATLAS has returned to the morning sky, now drifting through Virgo in the hours before sunrise. BBC Sky
11 November 2025
Government Shutdown Panic: Stocks Tumble, Jobs Data Vanish & Millions Brace for Impact

Is the Government Shutdown Over Today? (Nov. 11, 2025) Status, What’s in the Senate Deal, and What Happens Next

Updated Nov. 11, 2025 — Veterans Day Short answer: No. As of today (11.11.2025), the U.S. federal government remains in a shutdown. The Senate passed a bill last night to end it, but the House is not voting until tomorrow at the earliest due to the Veterans Day holiday. Reuters+1 The Latest at a Glance (Nov. 11) What’s in the Senate Plan to Reopen the Government The Senate package blends short‑term funding with a mini‑bus of full‑year bills: Why the Shutdown Isn’t Over Today Even with the Senate’s 60–40 vote, the House must pass the measure and send it to
11 November 2025
U.S. Space Force Readies ‘Meadowlands’ & Remote Modular Terminal Jammers to Counter China; Space Force Association Pushes Awareness — Nov. 11, 2025

U.S. Space Force Awareness Drive Expands as ‘Meadowlands’ and RMT Jammers Near Fielding — Nov. 11, 2025 Update

Published: November 11, 2025 The Space Force Association is scaling a nationwide education push amid persistently low public awareness, while the U.S. Space Force readies two new satellite‑jamming systems—Meadowlands and the Remote Modular Terminal—to join its Counter Communications System. Here’s what changed today and why it matters. What’s new today Why the Space Force is campaigning so hard Public understanding of the Space Force remains thin. At the end of last year, Deputy CSO for Human Capital Katharine Kelley said “less than 8 percent” of the public even knows the service exists—a data point she offered in a public forum
11 November 2025
Stimulus Check October 2025: Rumors Debunked – What to Know as Shutdown Continues

Are $2,000 Stimulus Checks Coming? Trump’s Tariff ‘Dividend’ Plan, Supreme Court Risks, and What Michiganders Should Know (Nov. 11, 2025)

Updated November 11, 2025 Quick takeaways What exactly did Trump propose? Over the weekend and again on Monday, President Trump promoted the idea of paying Americans a $2,000 per-person “dividend” funded by tariff receipts, with high‑income earners excluded. He also said remaining proceeds would help reduce the national debt. The message came first in a Truth Social post and then in Oval Office remarks. The Washington Post+1 Can the White House send checks without Congress? Short answer: No. Tariffs are taxes paid by importers to U.S. Customs and then deposited into the Treasury’s general fund; Congress must appropriate money before
11 November 2025
GSK (GSK) news today — Nov 11, 2025: New AN2 TB collaboration, buyback activity filed, shares test 12‑month high

GSK (GSK) news today — Nov 11, 2025: New AN2 TB collaboration, buyback activity filed, shares test 12‑month high

GSK plc (NYSE: GSK; LSE: GSK) generated several headlines today: a fresh research tie‑up in tuberculosis drug discovery, confirmation of ongoing share repurchases via a new U.K. regulatory filing, and a U.S.‑listed share price that pushed to a new 12‑month high intraday. BioSpace+2 1) New research collaboration targets TB AN2 Therapeutics announced a collaboration with GSK to advance boron‑based leucyl‑tRNA synthetase (LeuRS) inhibitors for tuberculosis. The effort is supported by a third year of Gates Foundation funding and builds on prior work between AN2 scientists and GSK’s Global Health R&D team, according to the release. Thomas Breuer, GSK’s Chief Global
11 November 2025
Vor Biopharma (VOR) Prices $100M Stock Offering at $10; Shares Slide as Investors Weigh Dilution — Nov. 11, 2025

Vor Biopharma (VOR) Prices $100M Stock Offering at $10; Shares Slide as Investors Weigh Dilution — Nov. 11, 2025

What happened today Vor Biopharma Inc. (NASDAQ: VOR) priced an underwritten public offering of 10 million common shares at $10.00 per share for $100 million in expected gross proceeds. The company granted underwriters a 30‑day option to purchase up to 1.5 million additional shares. Vor expects the transaction to close on or about Wednesday, Nov. 12, 2025, subject to customary conditions. J.P. Morgan, Jefferies, Citigroup, and TD Cowen are joint book‑running managers. The deal is being made under a shelf registration declared effective on March 31, 2025; a final prospectus supplement will be filed with the SEC. GlobeNewswire+1 How the
11 November 2025
Brookfield Renewable (BEP) Slides After $650M Equity Raise: Proceeds Target Isagen Stake & Baseload Growth (11/11/2025)

Brookfield Renewable (BEP) Slides After $650M Equity Raise: Proceeds Target Isagen Stake & Baseload Growth (11/11/2025)

Brookfield Renewable Partners L.P. (NYSE: BEP; TSX: BEP.UN) traded lower today after unveiling a fresh equity financing package tied to its push into “firm” clean power—including hydro and nuclear—and the recently completed increase in its stake in Colombia’s Isagen. Here’s what changed today, why it matters, and what’s next for investors. Key takeaways What happened today BEP units fell in morning trading after Monday’s after‑hours weakness, with market desks citing dilution from a new unit sale. Coverage noted the decline was linked to the US$650M capital raise unveiled the prior evening. MarketWatch+1 On the TSX, MarketWatch reported the Canadian line
11 November 2025
Vodafone (VOD) lifts dividend for first time in 8 years, launches €500m buyback and targets top‑end FY26 guidance

Vodafone (VOD) lifts dividend for first time in 8 years, launches €500m buyback and targets top‑end FY26 guidance

Vodafone Group Plc (LSE: VOD; NASDAQ: VOD) set out a markedly more shareholder‑friendly playbook today, guiding to the top end of its FY26 outlook, signalling its first full‑year dividend increase since 2018 (up 2.5%), and starting a new €500 million share buyback. The stock jumped ~5% toward 94p, helping push the FTSE 100 to a fresh record intraday high. The Standard+3Reuters+3investors.vodafone.com+3 What changed today Why it happened: Germany turned, UK integration accelerated, Africa remained strong Capital returns: dividend details & buyback mechanics Market reaction Shares rose around 5% to ~94p after the release, and the FTSE 100 notched a record
11 November 2025
LivePerson (LPSN) Soars After Citron Shout‑Out: Q3 Beat, Guidance Lift, and AI ‘Conversation Simulator’ Fuel Rally — 11/11/2025

LivePerson (LPSN) Soars After Citron Shout‑Out: Q3 Beat, Guidance Lift, and AI ‘Conversation Simulator’ Fuel Rally — 11/11/2025

LivePerson, Inc. (NASDAQ: LPSN) jumped sharply on Tuesday after a bullish note from Citron Research added fuel to momentum from the company’s third‑quarter results released late Monday. As of mid‑afternoon, shares traded near $6.25 and touched an intraday high of $7.50 (roughly +43% versus Monday’s close), reflecting investor enthusiasm around an earnings beat and the company’s new Conversation Simulator AI product. Investing What’s moving the stock today (Nov. 11) Key numbers & guidance Why “raised”: In August, LivePerson’s full‑year 2025 outlook called for revenue of $230M–$240M and adjusted EBITDA of –$3M to $7M. Monday’s update increases the low end of
Supply@ME Capital (LON: SYME) today — 11 Nov 2025: No new RNS; AGM confirmed for 4 Dec as shares trade around 0.004p

Supply@ME Capital (LON: SYME) today — 11 Nov 2025: No new RNS; AGM confirmed for 4 Dec as shares trade around 0.004p

Updated Tuesday, 11 November 2025 (UK time). Key takeaways Share price today (11 Nov 2025) In mid‑session dealing, SYME traded around 0.004p, with bid/ask at 0.003p/0.005p and an intraday range of 0.0035p to 0.0045p. Reported turnover was ~629.7 million shares. London South East data (delayed) also shows a wide spread typical of micro‑cap liquidity. Recent prints included trades time‑stamped around 14:55 UK time. London South East For perspective, the page lists a 52‑week range of 0.0015p–0.016p and ~71.73bn shares in issue, implying a market cap c. £2.9m at today’s quoted levels. London South East Note: Live prices on free sites
11 November 2025
The RealReal (REAL) spikes to new highs after Q3 beat; Wall Street lifts targets to $15–$16 — all the news investors need today (Nov. 11, 2025)

The RealReal (REAL) spikes to new highs after Q3 beat; Wall Street lifts targets to $15–$16 — all the news investors need today (Nov. 11, 2025)

The luxury resale leader topped Q3 estimates Monday and raised guidance. By Tuesday, shares hit fresh 52‑week highs as BTIG, UBS, Northland, KeyBanc and Baird updated calls. The RealReal, Inc. (NASDAQ: REAL) extended Monday evening’s earnings momentum into Tuesday’s session, touching a new 52‑week high intraday as multiple brokers boosted price targets following the company’s Q3 2025 beat and a higher full‑year outlook. GlobeNewswire Today’s (Nov. 11) headlines at a glance What The RealReal reported (Q3 2025) Top line & activity Profitability & cash AP’s earnings snapshot also flagged a $54.1M quarterly loss and $173.6M revenue, consistent with the company’s
11 November 2025
Caledonian Holdings (CHP.L) pops on 11 November: price crosses key averages; no new RNS as AlbaCo deal continues to set the tone

Caledonian Holdings (CHP.L) pops on 11 November: price crosses key averages; no new RNS as AlbaCo deal continues to set the tone

Dateline: London — 11 November 2025 (14:50 GMT) Summary: Micro‑cap investor Caledonian Holdings plc (AIM: CHP) traded firmly higher today, with the share price up around 33% to 0.004p by mid‑afternoon. The move came without any fresh regulatory announcements; instead, momentum appears to reflect the market’s ongoing digestion of October’s AlbaCo share‑swap and last week’s admission of 12.5 billion new shares, alongside a buoyant London market on rate‑cut hopes. FT Markets+2Investegate+2 Key takeaways for 11 Nov 2025 What moved CHP.L today Technical tailwinds. With no new company‑specific news, traders focused on tape action. CHP printed 0.004p (+33% vs. prior close), with
11 November 2025
PubMatic (PUBM) Soars on Q3 Beat as Analysts Hike Targets to $20; AI & CTV Momentum in Focus — Nov. 11, 2025

PubMatic (PUBM) Soars on Q3 Beat as Analysts Hike Targets to $20; AI & CTV Momentum in Focus — Nov. 11, 2025

As of 15:42 UTC on Nov. 11, PubMatic shares last traded around $10.40, up sharply intraday following last night’s earnings and a flurry of analyst target increases. Why PUBM is moving today Key numbers & operating highlights Third quarter (ended Sept. 30, 2025): Growth drivers called out by management: Q4 2025 outlook (company guidance) PubMatic guided Q4 revenue to $73M–$77M and adjusted EBITDA to $19M–$21M (~27% margin at the midpoint). Guidance factors in FX headwinds and notes an impact from one top DSP buyer. Nasdaq What Wall Street said today Strategy check: CTV, SPO, and AI Management emphasized three pillars:
11 November 2025
EME.L Soars on Duyung PSC Update: Empyrean Energy Jumps 90%+ as Conrad Asia Seeks Farm‑Down Completion (11 November 2025)

EME.L Soars on Duyung PSC Update: Empyrean Energy Jumps 90%+ as Conrad Asia Seeks Farm‑Down Completion (11 November 2025)

London — 11 November 2025 — Empyrean Energy Plc (AIM: EME) surged on Tuesday after the company flagged an operator update at Indonesia’s Mako Gas Field, part of the Duyung Production Sharing Contract (PSC). In a regulatory notice at 11:42 (UK time), Empyrean said operator Conrad Asia Energy placed its ASX‑listed securities in a trading halt pending an announcement “in relation to the completion of the proposed farm down of their 75% interest” in the Duyung PSC, where Empyrean holds 8.5%. Empyrean added it will provide an update to the AIM market “as soon as possible.” Investegate Share price and
11 November 2025
Grab (GRAB) News Today — Nov 11, 2025: SoftBank fuels GoTo shake‑up, Grab launches lane‑level GPS pilot, AGM date set; GoTo says no deal yet

Grab (GRAB) News Today — Nov 11, 2025: SoftBank fuels GoTo shake‑up, Grab launches lane‑level GPS pilot, AGM date set; GoTo says no deal yet

Merger chatter intensifies—but no agreement as of today A Bloomberg report today says a group of GoTo backers—including SoftBank—is pushing to replace CEO Patrick Walujo, a shake‑up that investors view as potentially smoothing the way for renewed Grab–GoTo deal discussions. Bloomberg In a same‑day update from Dow Jones Newswires, GoTo stated that no decision or agreement has been made with Grab, addressing market speculation directly. Morningstar For context, Indonesia’s government confirmed last week that it is discussing a potential Grab–GoTo combination, underscoring the sector’s strategic importance for jobs and the economy—yet any transaction would still face regulatory review. Reuters Regulatory
11 November 2025
JD.L: JD Sports Edges Higher as Buyback Continues — All the News Investors Need on 11 November 2025

JD.L: JD Sports Edges Higher as Buyback Continues — All the News Investors Need on 11 November 2025

Date: 11 November 2025 JD Sports Fashion (LSE: JD., ticker JD.L) traded modestly higher today as the retailer reported another daily share repurchase under its £100m buyback. Here’s today’s price action, the fresh RNS, and the next catalysts investors should watch Quick take JD.L share price snapshot (11 Nov 2025) JD Sports shares ticked higher in London, with last trade c. 85p, a day range of 84.06p–85.60p, and a 52‑week range of 61.04p–122.55p. Previous close was 84.76p; today’s open 85.30p. These figures position the stock near the lower third of its 12‑month range despite today’s uptick. Reuters Today’s JD Sports
11 November 2025
Tesla (TSLA) Today — Nov. 11, 2025: China Sales Sink to 3‑Year Low, Model Y & Cybertruck Chiefs Exit, as Musk’s AI Pivot Takes Center Stage

Tesla (TSLA) Today — Nov. 11, 2025: China Sales Sink to 3‑Year Low, Model Y & Cybertruck Chiefs Exit, as Musk’s AI Pivot Takes Center Stage

On Nov. 11, 2025, Tesla’s China sales hit a three‑year low, two vehicle‑program leaders departed, shareholders’ $1T Musk award reverberated, and fresh commentary put Optimus and FSD ambitions back in the spotlight. TSLA slips intraday. TSLA stock snapshot (intraday) As of publication, TSLA trades around $435–$443 with a modest decline on the day. What’s new today (Nov. 11, 2025) 1) China sales slump to a 3‑year low Fresh China Passenger Car Association data reported by Reuters show Tesla delivered 26,006 vehicles in China during October, a three‑year low and ‑35.8% YoY, while exports from Shanghai rose to 35,491 (a two‑year
Shell’s $2 Billion Nigeria Gas Gamble Ignites LNG Boom Amid $8 B Investment Surge

SHEL.L: Shell plc Hits Fresh 52‑Week High as It Appeals Venture Global LNG Ruling — All the Key News on 11 November 2025

Updated: 11 November 2025 Key Takeaways 1) Litigation Watch: Shell Appeals Venture Global Arbitration Loss Shell confirmed it has petitioned the New York Supreme Court to vacate an arbitration award it lost in August in its dispute with Venture Global LNG over non‑delivery of cargoes during Calcasieu Pass’s extended “start‑up” period. In the new filing, Shell argues the tribunal’s decision should be set aside because Venture Global allegedly withheld key evidence; Shell also points to BP’s October arbitration victory as context for its appeal. Venture Global says Shell had a full and fair process and calls the petition “without merit.”
11 November 2025

Stock Market Today

AstraZeneca stock price: What could move AZN next week as earnings loom

AstraZeneca stock price: What could move AZN next week as earnings loom

7 February 2026
AstraZeneca shares rose Friday, closing at $193.03 in New York, up 3.1%, and 14,104p in London, up 0.9%. The company reports full-year and Q4 2025 results Tuesday, with investors focused on 2026 guidance. The FDA this week issued a complete response letter for a subcutaneous Saphnelo filing, while granting Priority Review to Datroway for breast cancer. AstraZeneca recently shifted its primary U.S. listing to the NYSE.
Go toTop